Ublituximab

Briumvi 150 mg concentraat voor oplossing voor infusie

Concentraat voor oplossing voor infusieNetherlandsAuthorisedAuthorised 31 May 2023

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

BriumviEuropean UnionAuthorised

BriumviBrazil · Neuraxpharm Brasil Importacao e Distribuicao de Medicamentos Ltda.Same brand
Briumvi 150 MG Concentrado Para Solucion Para PerfusionSpain · 150 mg · concentrado para solución para perfusión · Neuraxpharm Pharmaceuticals S.L.Same brand
BriumviEuropean Union · Neuraxpharm Pharmaceuticals S.L.Same brand
BriumviCroatiaSame brand
BriumviItaly · Concentrato per soluzione per infusione · Neuraxpharm Pharmaceuticals, S.LSame brand
BriumviUnited States · 25 MG/ML · injectable · TG Therapeutics, INC

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ublituximab

Briumvi 150 mg concentraat voor oplossing voor infusie

Concentraat voor oplossing voor infusieNetherlandsAuthorisedAuthorised 31 May 2023

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

BriumviEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ublituximab
Dosage form: Concentraat voor oplossing voor infusie
Route: Intraveneus gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 31 May 2023
Registration: EU/1/23/1730
Marketing authorisation holder: Neuraxpharm Pharmaceuticals S.L.
ATC code: L04AG14
Group: Antineoplastic and immunomodulating agents
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/005914
EU number: EU/1/23/1730